Yuki Hoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuki Hoda has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Go Akamatsu
National Institutes for Quantum Science and Technology
2 shared publications - Michio Senda
Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe, Japan
2 shared publications - Tomohiko Yamane
Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe, Japan
2 shared publications - Yasuhiko Ikari
Department of Molecular Imaging Research, Kobe City Medical Center General Hospital, Kobe
2 shared publications - Aki Marugami
Department of Diagnostic and Interventional Radiology, Nara Medical University, 840 Shijo-cho, Kashihara-city, Nara 634-8522, Japan
1 shared publication Gensho Tanke
Department of Gastroenterology, Kobe City Medical Center General Hospital, Kobe, Japan
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , 555-564
First-In-Human Evaluation of [18F]Fluproxadine for Norepinephrine Transporter PET
Background: Current norepinephrine transporter (NET) tracers used for cardiac sympathetic imaging and oncology are limited by radiosynthesis complexity, suboptimal image quality, or operational constraints. [ 18 F]fluproxadine (formerly [ 18 F]AF78) was developed to address these limitations by providing high NET affinity, favorable biodistribution, and an operationally straightforward radiosynthesis. We therefore conducted the first-in-human evaluation of this new class of [ 18 F] labeled NET PET tracer to assess its safety, biodistribution, radiation dosimetry, and imaging characteristics. Patients and Methods: In a prospective study, 4 healthy adult volunteers received [ 18 F]fluproxadine (101.8–204.0 MBq). Dynamic whole-body PET/CT acquisitions were obtained 10 times from 1 to 232 minutes postinjection, and vital signs, laboratory tests, and adverse events were monitored. Time-activity curves were generated for major organs, including myocardium from the whole-body scans, and organ-absorbed doses and effective dose were estimated using OLINDA/EXM v2.0 from time-integrated activities. Myocardial uptake and target-to-background behavior were assessed using semiquantitative methods. Radiosynthesis performance and key operational steps were documented to assess practical scalability. Results: Radiosynthesis of [ 18 F]fluproxadine was operationally straightforward with encouraging yields and fewer specialized steps than some legacy tracers. Imaging was completed without serious adverse events. Biodistribution showed predominant renal clearance; biliary excretion was not observed within the imaging window. Highest organ doses were to the urinary bladder wall and kidneys, with additional uptake in liver, thyroid, salivary glands, and myocardium. The effective dose was 21.6±1.5 µSv/MBq. Myocardial uptake was clearly visualized on whole-body images with favorable target-to-background characteristics at delayed time points, consistent with NET biology and supporting practical cardiac imaging windows. Conclusions: [ 18 F]fluproxadine demonstrated clear myocardial uptake, acceptable radiation dosimetry comparable to typical 18 F PET agents, and an early safety profile without serious adverse events.
- 27 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , 555-564
Open AccessFirst-In-Human Evaluation of [18F]Fluproxadine for Norepinephrine Transporter PET
Background: Current norepinephrine transporter (NET) tracers used for cardiac sympathetic imaging and oncology are limited by radiosynthesis complexity, suboptimal image quality, or operational constraints. [ 18 F]fluproxadine (formerly [ 18 F]AF78) was developed to address these limitations by providing high NET affinity, favorable biodistribution, and an operationally straightforward radiosynthesis. We therefore conducted the first-in-human evaluation of this new class of [ 18 F] labeled NET PET tracer to assess its safety, biodistribution, radiation dosimetry, and imaging characteristics. Patients and Methods: In a prospective study, 4 healthy adult volunteers received [ 18 F]fluproxadine (101.8–204.0 MBq). Dynamic whole-body PET/CT acquisitions were obtained 10 times from 1 to 232 minutes postinjection, and vital signs, laboratory tests, and adverse events were monitored. Time-activity curves were generated for major organs, including myocardium from the whole-body scans, and organ-absorbed doses and effective dose were estimated using OLINDA/EXM v2.0 from time-integrated activities. Myocardial uptake and target-to-background behavior were assessed using semiquantitative methods. Radiosynthesis performance and key operational steps were documented to assess practical scalability. Results: Radiosynthesis of [ 18 F]fluproxadine was operationally straightforward with encouraging yields and fewer specialized steps than some legacy tracers. Imaging was completed without serious adverse events. Biodistribution showed predominant renal clearance; biliary excretion was not observed within the imaging window. Highest organ doses were to the urinary bladder wall and kidneys, with additional uptake in liver, thyroid, salivary glands, and myocardium. The effective dose was 21.6±1.5 µSv/MBq. Myocardial uptake was clearly visualized on whole-body images with favorable target-to-background characteristics at delayed time points, consistent with NET biology and supporting practical cardiac imaging windows. Conclusions: [ 18 F]fluproxadine demonstrated clear myocardial uptake, acceptable radiation dosimetry comparable to typical 18 F PET agents, and an early safety profile without serious adverse events.
- 6 March 2026
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 44 (7) , 1308-1309
18F-FAPI-74 versus 18F-FDG in synchronous pancreatic cancer and follicular lymphoma
- 6 March 2026
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 44 (7) , 1308-1309
18F-FAPI-74 versus 18F-FDG in synchronous pancreatic cancer and follicular lymphoma
- Open Access
- 4 December 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Optimizing [18F]FAPI-74 PET/CT imaging: insights from Early-phase tumor uptake and tissue contrast
Background: Fibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that 68 Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [ 18 F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [ 18 F]FAPI-74 PET/CT imaging. Methods: The cohort comprised 32 patients who underwent whole-body [ 18 F]FAPI-74 PET/CT at three time points: 10, 30, and 60 min after administration. The uptake of [ 18 F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean. Results: The uptake of [ 18 F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60 min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively). Conclusions: TBRs were highest at 60 min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system. Trial registration: UMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594 .
- 4 December 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Open AccessOptimizing [18F]FAPI-74 PET/CT imaging: insights from Early-phase tumor uptake and tissue contrast
Background: Fibroblast activation protein inhibitor (FAPI) is a novel PET tracer that targets various malignant tumors. Although some studies have demonstrated that 68 Ga-labeled FAPI PET provides diagnostic images shortly after injection, reports on early-phase imaging using [ 18 F]FAPI-74 are limited. This study evaluated the diagnostic potential of early-phase [ 18 F]FAPI-74 PET/CT imaging. Methods: The cohort comprised 32 patients who underwent whole-body [ 18 F]FAPI-74 PET/CT at three time points: 10, 30, and 60 min after administration. The uptake of [ 18 F]FAPI-74 in normal organs and tumors at each time point was evaluated and compared using standardized uptake value (SUV). The contrast between tumor and background uptake was assessed using tumor-to-blood ratios (TBRs), calculated as the ratio of tumor SUVmax to blood pool SUVmean. Results: The uptake of [ 18 F]FAPI-74 in most organs gradually decreased, except in the mammary gland and nipple. Moreover, uptake due to the excretion increased over time in the gallbladder, and bile duct. Among the 72 lesions identified across patients, the median SUVmax of the tumors remained relatively stable across the time points (5.00, 5.16, and 5.11 at 10, 30, and 60 min, respectively), while the median TBRs gradually increased (1.57, 2.24, and 2.94, respectively). Subgroup analysis revealed a similar pattern of increasing median TBRs in primary tumors (2.76, 3.72, and 4.04, respectively), lymph node metastases and peritoneal dissemination (1.67, 2.47, and 3.58, respectively), and lung metastases (0.99, 1.35, and 1.48, respectively). Conclusions: TBRs were highest at 60 min after administration. However, early-phase imaging was considered useful because of its sufficient diagnostic contrast and low physiological uptake in the biliary system. Trial registration: UMIN Clinical Trials Registry, UMIN000051687. Registered 22 July 2023, https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_his_list.cgi?recptno=R000058594 .
- Open Access
- 31 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (3) , 306
Multimodality Imaging of Primary Hepatic Lymphoma: A Case Report and a Literature Review
Primary hepatic lymphoma (PHL) is a rare form of non-Hodgkin lymphoma primarily affecting the liver. We present a case of an 84-year-old man diagnosed with PHL, incidentally detected during abdominal ultrasonography. The ultrasonography showed a hypoechoic nodule. When examined by CEUS, the nodule showed hyperenhancement in the arterial phase and hypoenhancement in the portal and late phases. Conversely, CECT demonstrated hypoenhancement through all the phases. The patient declined a tumor biopsy and opted for follow-up care. Ten months later, the lobular mass had increased from 15 mm to 65 mm, presenting as hypoechogenic and demonstrating the “vessel-penetrating sign” on color Doppler imaging. CEUS revealed reticulated enhancement, indicating intratumoral vessels. The mass displayed hypoattenuation on plain CT, hypointensity in T1-weighted images, and hyperintensity in T2-weighted images and exhibited significant restriction in diffusion-weighted images. Both CECT and contrast-enhanced MRI exhibited hypoenhancement. The patient underwent a partial hepatic segmentectomy, and the mass was pathologically diagnosed as a diffuse large B-cell lymphoma. Subsequent postoperative radiological examinations revealed no other lesions, confirming the diagnosis of PHL. Our report highlights specific ultrasonographic signs of PHL observed from an early stage and presents a review of the relevant literature.
- 31 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (3) , 306
Open AccessMultimodality Imaging of Primary Hepatic Lymphoma: A Case Report and a Literature Review
Primary hepatic lymphoma (PHL) is a rare form of non-Hodgkin lymphoma primarily affecting the liver. We present a case of an 84-year-old man diagnosed with PHL, incidentally detected during abdominal ultrasonography. The ultrasonography showed a hypoechoic nodule. When examined by CEUS, the nodule showed hyperenhancement in the arterial phase and hypoenhancement in the portal and late phases. Conversely, CECT demonstrated hypoenhancement through all the phases. The patient declined a tumor biopsy and opted for follow-up care. Ten months later, the lobular mass had increased from 15 mm to 65 mm, presenting as hypoechogenic and demonstrating the “vessel-penetrating sign” on color Doppler imaging. CEUS revealed reticulated enhancement, indicating intratumoral vessels. The mass displayed hypoattenuation on plain CT, hypointensity in T1-weighted images, and hyperintensity in T2-weighted images and exhibited significant restriction in diffusion-weighted images. Both CECT and contrast-enhanced MRI exhibited hypoenhancement. The patient underwent a partial hepatic segmentectomy, and the mass was pathologically diagnosed as a diffuse large B-cell lymphoma. Subsequent postoperative radiological examinations revealed no other lesions, confirming the diagnosis of PHL. Our report highlights specific ultrasonographic signs of PHL observed from an early stage and presents a review of the relevant literature.